Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life
Carcinoma, Renal Cell
Robotic Surgical Procedures
Increased monitoring among men with mPCa significantly increases health care costs, without a definitive improvement in survival nor quality of care at EOL noted. Monitoring for disease progression outside of clinical trials should be reserved for those in whom findings will change management. Cancer 2018. © 2018 American Cancer Society.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency